Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavia Costanza

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Reviews in Endocrine & Metabolic Disorders|August 21, 2024
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapySabrina Chiloiro, Alessandra Vicari, Ginevra Mongelli, et al.
Pituitary|July 11, 2026
The metabolic effects of glucocorticoid replacement therapy in patients with secondary adrenal insufficiency due to hypothalamic-pituitary diseases: results from a retrospective and longitudinal studySabrina Chiloiro, Alessandra Vicari, Antonella Giampietro, et al.
Frontiers in Endocrinology|September 16, 2024
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot studySabrina Chiloiro, Flavia Costanza, Antonella Giampietro, et al.
Pituitary|January 19, 2026
Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory studySabrina Chiloiro, Flavia Costanza, Alessandra Vicari, et al.
Pituitary|May 25, 2025
Genes of the "regulation of lymphocyte activation" pathway may influence immune cells infiltration in growth hormone secreting pituitary tumorsSabrina Chiloiro, Flavia Costanza, Giovanni Luca Scaglione, et al.
Pituitary|December 26, 2024
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegalySabrina Chiloiro, Antonella Giampietro, Penelope Giambò, et al.
Pituitary|September 7, 2025
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohortSabrina Chiloiro, Antonella Giampietro, Raffaele Migliore, et al.
International Journal of Molecular Sciences|February 10, 2024
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?Sabrina Chiloiro, Ettore Domenico Capoluongo, Flavia Costanza, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 1, 2026
Clinical Exome Sequencing Study in a Cohort of Growth Hormone-Secreting Pituitary AdenomasFlavia Costanza, Giovanni Luca Scaglione, Filippo Russo, et al.
BMC Cancer|March 21, 2020
MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North SardiniaMatteo Floris, Daria Sanna, Paolo Castiglia, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Reviews in Endocrine & Metabolic Disorders|August 21, 2024
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapySabrina Chiloiro, Alessandra Vicari, Ginevra Mongelli, et al.
Pituitary|July 11, 2026
The metabolic effects of glucocorticoid replacement therapy in patients with secondary adrenal insufficiency due to hypothalamic-pituitary diseases: results from a retrospective and longitudinal studySabrina Chiloiro, Alessandra Vicari, Antonella Giampietro, et al.
Frontiers in Endocrinology|September 16, 2024
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot studySabrina Chiloiro, Flavia Costanza, Antonella Giampietro, et al.
Pituitary|January 19, 2026
Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory studySabrina Chiloiro, Flavia Costanza, Alessandra Vicari, et al.
Pituitary|May 25, 2025
Genes of the "regulation of lymphocyte activation" pathway may influence immune cells infiltration in growth hormone secreting pituitary tumorsSabrina Chiloiro, Flavia Costanza, Giovanni Luca Scaglione, et al.
Pituitary|December 26, 2024
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegalySabrina Chiloiro, Antonella Giampietro, Penelope Giambò, et al.
Pituitary|September 7, 2025
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohortSabrina Chiloiro, Antonella Giampietro, Raffaele Migliore, et al.
International Journal of Molecular Sciences|February 10, 2024
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?Sabrina Chiloiro, Ettore Domenico Capoluongo, Flavia Costanza, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 1, 2026
Clinical Exome Sequencing Study in a Cohort of Growth Hormone-Secreting Pituitary AdenomasFlavia Costanza, Giovanni Luca Scaglione, Filippo Russo, et al.
BMC Cancer|March 21, 2020
MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North SardiniaMatteo Floris, Daria Sanna, Paolo Castiglia, et al.
Pageof 3